Biotechnology - Licensing, Anti-virals


Current filters:


Popular Filters

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen


US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

Cytos out-licenses VLP platform for hep B infections to OnCore Biopharma


Switzerland-based Cytos Biotechnology has executed an exclusive license agreement granting privately-held…

Anti-viralsBiotechnologyCytos BiotechnologyLicensingOnCore BioPharma

Merck gains rights to NewLink Genetics investigational Ebola vaccine


US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

Imaxio signs option for a license agreement with DKFZ


French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…


NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018


Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead


US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen


US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

BioAlliance Pharma licenses Sitavig to Innocutis in North America


French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Vertex sells Incivo royalty rights to Janssen for $152 million


Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Valneva licenses EB66 to IAVI for preventive HIV vaccine


Biotech firm Valneva says that it has licensed the use of its EB66 cell line to the International AIDS…


Valneva enters deals with Delta-Vir


Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…


Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs


Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…


Immune Design and Medicago link up to develop flu vaccines


Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

BioLineRx collaborates with Chinese firm on hep C drug BL-8030


Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx


US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Third deal for Ascletis, which gains China market rights from Janssen to a clinical stage HIV protease inhibitor


USA and China-based biotech firm Ascletis Pharmaceuticals says it has licensed development, manufacturing…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologyJanssenJohnson & JohnsonLicensingTMC310911

Roche teams up with Ascletis on hep C treatments for China


Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Silencing investor concerns? Alnylam achieves RNAi milestone


US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines



Back to top